Inhibitor treatment by rituximab in congenital haemophilia a two case reports;Immuntoleranztherapie mit Rituximab bei Patienten mit Angeborener Hamophilie a und Inhibitorbildung - Zwei Fallberichte

Hamostaseologie

Volumn 29, Issue 2, 2009, Pages 151-154

  Streif, W ^a,c   Ettingshausen, C Escuriola ^b   Linde, R ^b   Kropshofer, G ^a   Zimmerhackl, L B ^a   Kreuz, W ^c  

^a Universitatsklinik fur Kinder und Jugendheilkunde Innsbruck   (Austria)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Haemophilia A; Immune tolerance induction; Inhibitor; Rituximab

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; VON WILLEBRAND FACTOR;

ADOLESCENT; ARTICLE; ASPERGILLOSIS; B LYMPHOCYTE; BLEEDING; CASE REPORT; DRUG EFFICACY; HEMOPHILIA A; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGICAL TOLERANCE INDUCTION THERAPY; IMMUNOMODULATION; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 66749095668     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617028     Document Type: Article

References (18)

1. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
2. Kreuz W, Becker S, Lenz E et al. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemost 1995; 21: 382-389.
3. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: pathophysiology. Haemophilia 2004; 10 (Suppl 4): 146-151.
4. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-612.
5. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-195.
6. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 (Suppl 1): 49-54.
7. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
8. Mauser-Bunschoten EP, Nieuwenhuis HK, Roo- sendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-988.
9. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-950.
10. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12 (Suppl 6): 1-7.
11. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859-866.
12. Brackmann HH, Lenk H, Scharrer I et al. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999; 5: 203-206.
13. Kessel C, Konigs C, Linde R et al. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Mol Immunol 2008; 46: 8-15.
14. Linde R, Ettinghausen CE, Voigt B et al. First successful inhibitor elimination with a new protocol in a high responding hemophilia A patient after failure of various immune tolerance induction regimens. Blood 2001; 98: 2236a.
15. Franchini M, Mengoli C, Lippi G et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008; 14: 903-912.
16. Carcao M, St Louis J, Poon MC et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7-18.
17. Mathias M, Khair K, Hann I, Liesner R. Rituxi- mab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-368.
18. Kreuz W. The role of VWF for the success of immune tolerance induction. Thromb Res 2008; 122 (Suppl 2): S7-S12.